Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2017

View Archived Issues

Aptevo Therapeutics to sell hyperimmune commercial products to Saol Therapeutics

Fresenius Kabi closes acquisition of Merck KGaA's biosimilars business

Takeda and Noile-Immune Biotech enter a collaboration to advance next generation CAR-T cell therapy

GlaxoSmithKline, ViiV identify new HIV allosteric integrase inhibitors

ReViral begins dosing in phase IIa study of RV-521 for RSV

Promising RORgammaT inhibitors discovered at Merck & Co.

FDA places clinical hold on phase I studies of UCART-123

Increased SIRT4 expression linked to accelerated heart failure development

Novartis reports promising data from phase III study of fingolimod in pediatric MS

Enrollment completed in phase IIb study of BGS-649 for hypogonadotropic hypogonadism

PMV Pharmaceuticals describes novel compounds restoring mutant p53 function

Concert Pharmaceuticals presents new PPARalpha, PPARdelta agonists

Vanderbilt University divulges novel muscarinic acetylcholine M1 receptor modulators

Novel bile acid receptor agonists discovered at Alios BioPharma

Golden Biotechnology presents new compounds for liver cancer

First-in-human phase I results for (Z)-endoxifen in endocrine-refractory metastatic breast cancer

Axxam and Sanofi begin neurodegeneration research collaboration

Funding pledged to Global Antibiotic Research and Development Partnership

New phase I/II study investigates H3B-6545 in advanced ER-positive, HER2-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...